Konen Franz Felix, Möhn Nora, Witte Torsten, Schefzyk Matthias, Wiestler Miriam, Lovric Svjetlana, Hufendiek Karsten, Jendretzky Konstantin Fritz, Gingele Stefan, Schwenkenbecher Philipp, Sühs Kurt-Wolfram, Friese Manuel A, Klotz Luisa, Pul Refik, Pawlitzki Marc, Hagin David, Kleinschnitz Christoph, Meuth Sven G, Skripuletz Thomas
Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Department of Rheumatology and Clinical Immunology, Hannover Medical School, 30625 Hannover, Germany.
Autoimmun Rev. 2025 Mar 26;24(4):103754. doi: 10.1016/j.autrev.2025.103754. Epub 2025 Jan 20.
A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical compounds within clinical trials has been ignited. Emerging novel medications with innovative mechanisms of action are being introduced. Those mechanisms of action include a broad therapeutic spectrum of substances targeting various protein kinases, some of which could also be used for the treatment of other autoimmune-mediated diseases. The advancement of new compounds could therefore enable a more personalized approach in treating MS, taking into consideration patients' co-existing autoimmune-mediated diseases. In this review, we discuss potential compounds targeting protein kinases, currently under investigation in clinical trials for various autoimmune diseases that could become viable treatment options for MS and comorbid autoimmune conditions in the future.
目前已有多种免疫调节疗法可用于治疗多发性硬化症（MS）。通过基础研究获得的关于MS潜在病理过程的深入认识，激发了在临床试验中探索更多医学化合物的热情。具有创新作用机制的新型药物不断涌现。这些作用机制包括针对各种蛋白激酶的广泛治疗谱，其中一些也可用于治疗其他自身免疫介导的疾病。因此，新化合物的进展可以在考虑患者并存的自身免疫介导疾病的情况下，实现更个性化的MS治疗方法。在这篇综述中，我们讨论了目前正在各种自身免疫性疾病临床试验中研究的、可能成为未来MS和合并自身免疫性疾病可行治疗选择的靶向蛋白激酶的潜在化合物。
